蘭蔻產品廣告遭美藥監局警告

美國食品藥品監督管理局日前對法國歐萊雅集團發出警告，要求其下屬的蘭蔻美國分公司停止在蘭蔻系列護膚品廣告中使用類似藥品功效的描述語言。藥監局表示，蘭蔻系列的精華肌底修護晚霜和菁純臻顏再生眼霜等產品廣告稱這些產品可以“提升基因活力”或“刺激細胞再生”以達到延緩衰老的功效。警告信指出，任何旨在對人體結構和功能產生影響的產品均應被歸爲藥物，而未向藥監局提出申請並證明其產品的安全和功效的公司是不能在美國銷售這些藥物的。藥監局稱，如果不修正上述廣告詞，他們將採取強制措施，比如沒收產品或對生產商和銷售商實行禁令等。

Regulators warned L'Oreal, the world's biggest cosmetics group, to stop advertising skincare products using language that makes them sound like drugs.

The U.S. Food and Drug Administration said Lancome USA, a L'Oreal unit, claimed some of its skin creams could "boost the activity of genes" or "stimulate cell regeneration" to reduce signs of aging.

Any product that is intended to affect the structure or function of the human body is classified as a drug, the FDA said, according to a warning letter posted on its website on Tuesday.

Companies are not allowed to sell drugs in the United States without submitting an application to the FDA proving their products are safe and effective and then winning FDA approval.

L'Oreal, a French company, was not immediately available for comment.

Some of the products mentioned in the letter, dated September 7, include Genifique Repair Youth Activating Night Cream and Absolue Eye Precious Cells Advanced Regenerating and Reconstructing Eye Cream.

On its website, Lancome describes the Genifique Repair cream, which costs $98 for a 1.7-ounce container, as "our first night care that boosts the activity of genes." The company cites an in-vitro test on genes to back up the claim.

The FDA said failure to fix the advertising claims could lead to enforcement actions, such as seizure of the products and injunctions against their manufacturers and distributors.